UCB (OTCMKTS:UCBJF) Sees Large Volume Increase – Here’s Why

UCB SA (OTCMKTS:UCBJF) saw unusually-high trading volume on Friday . Approximately 3,554 shares changed hands during mid-day trading, an increase of 380% from the previous session’s volume of 741 shares.The stock last traded at $321.05 and had previously closed at $310.00.

Analyst Upgrades and Downgrades

UCBJF has been the subject of several research analyst reports. Wolfe Research initiated coverage on shares of UCB in a report on Monday, February 23rd. They issued an “outperform” rating for the company. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a report on Monday, February 16th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company’s 50 day moving average is $295.40 and its 200-day moving average is $298.88.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.